Celtaxsys Inc.

Insmed Inc. is to take its potential first-in-class product INS1007 into late-stage trials on the basis of positive top-line data from its Phase II WILLOW study in adults with non-cystic fibrosis bro

Atlanta-based, private start-up Celtaxsys Inc. is gearing up to talk to the US FDA about using pulmonary exacerbations as the Phase III primary endpoint for its cystic fibrosis therapy acebilustat,

The progression of investigational products through a series of increasingly sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for commer

Derived from Strategic Transactions , Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biophar